General Electric�(NYSE:GE) has been on a tear ever since it announced its first-quarter earnings in April. At Monday�� closing price of $23.77, the stock price is up around 10 percent since the earnings announcement.
This rapid growth is unusual for GE, which is often thought of as stock that exhibits stable growth and attractive dividends. It is safe to say that shareholders are not complaining about GE�� recent success. With that being said, let�� use our CHEAT SHEET framework to decide whether GE can keep its positive momentum and if it is an OUTPERFORM, WAIT AND SEE, or STAY AWAY.
Catalysts For Growth
General Electric is a multinational conglomerate operating in four different industries: energy, technology, capital finance, and consumer and industrial products. GE is such a large and diversified company that it can almost be viewed as a proxy for the overall economy; thus, when the economy performs well, so does GE, and vice versa.
NEW! Discover a new stock idea each week for less than the cost of 1 trade. CLICK HERE for your Weekly Stock Cheat Sheets NOW!GE has benefited recently from higher consumer and industrial expenditures as the economy continues to rebound and the Fed continues its stimulus program. GE, the largest manufacturer of jet engines, saw a sharp increase in engine orders from both Boeing (NYSE:BA) and Airbus. GE should expect those orders to continue as both airplane manufacturers race for dominance in the widebody jet market. Moreover, GE Aviation has recently begun building a new factory in Asheville, North Carolina. The factory will manufacture ceramic matrix composites, a new technology that will improve fuel efficiency in its new LEAP jet engines and reduce greenhouse gas emissions. GE anticipates delivery of these LEAP engines to Boeing and Airbus in 2016.
Top 5 Information Technology Companies To Watch In Right Now: NextStage Inc (NXT)
NextStage, Inc. is a holding company. The Company is engaged in the management of its investments in shares of stocks of its subsidiaries. The Company�� subsidiaries include Mondex Philippines Inc. (MXP), Infinit-e Asia Inc. (Infinit-e Asia) and Technology Support Services, Inc. (TSSI). MXP operates a multi-application smart card system in Philippines. Infinit-e Asia is a software development company specializing on smart card and e-commerce solutions tailored to enhance the business of its clients. Infinit-e Asia develops smart card solutions for both real and online applications and on both contact and contactless platform. Infinit-e Asia�� spectrum of products and applications are classified as payments, data capture and security. TSSI is engaged in the business of business process outsourcing (BPO), applications service providers (ASP) and managed service providers (MSP). Advisors' Opinion:- [By Namitha Jagadeesh]
HSBC Holdings Plc (HSBA), Europe�� largest bank, slid 2.1 percent. International Consolidated Airlines Group SA (IAG) declined 2 percent as it canceled some of its flights following a disruption caused by one of its planes at Heathrow airport. Next Plc (NXT) retreated 2.4 percent as Morgan Stanley cut its recommendation on the shares.
Best Prefered Stocks To Buy Right Now: Vanguard Short-Term Bond ETF (BSV)
Vanguard Short-Term Bond ETF (the Fund) seeks to track the performance of a market-weighted bond index with a short-term, dollar-weighted average maturity. The Fund employs a passive management or indexing strategy designed to track the performance of the Barclays Capital U.S. 1-5 Year Government/Credit Bond Index (the Index). The Index includes all medium and larger issues of the United States Government, investment-grade corporate, and investment-grade international dollar-denominated bonds that have maturities of between 1 and 5 years and are publicly issued. The Fund invests by sampling the Index, meaning that it holds a range of securities that, in the aggregate, approximates the full Index in terms of key risk factors and other characteristics. All of the Fund�� investments will be selected through the sampling process, and at least 80% of its assets will be invested in bonds held in the Index. The Fund�� investment advisor is The Vanguard Group, Inc. Advisors' Opinion:- [By GURUFOCUS]
In addition to individual stocks several funds pay a monthly dividend. Below is a sampling of these:
Monthly Bond Funds- iShares Barclays 1-3 Year Credit Bond (CSJ) | Yield: 1.29%
- Vanguard Short-Term Bond ETF (BSV) | Yield: 1.25%
- Vanguard Intermediate-Term Bond ETF (BIV) | Yield: 2.96%
- Vanguard Long-Term Bond ETF (BLV) | Yield: 4.42%
Best Prefered Stocks To Buy Right Now: Cinemark Holdings Inc(CNK)
Cinemark Holdings, Inc. and its subsidiaries engage in the motion picture exhibition business. As of June 30, 2011, it operated 436 theatres with 4,983 screens in 39 states of the United States, as well as in Brazil, Mexico, and 11 other Latin American countries. The company is headquartered in Plano, Texas.
Advisors' Opinion:- [By Rich Smith]
As movie-theater operator Cinemark (NYSE: CNK ) exits the Mexican market, another "gringo" is expanding to fill the gap -- from even farther north of the border.
- [By John Udovich]
The shares of small cap IMAX Corporation (NYSE: IMAX) have slipped more than 10% this week on growth concerns - meaning it might be a good idea to take a closer look at the stock plus its performance�verses other cinema stocks like Carmike Cinemas, Inc (NASDAQ: CKEC), Cinemark Holdings, Inc (NYSE: CNK) and Regal Entertainment Group (NYSE: RGC) along with the PowerShares Dynamic Leisure & Entertainment ETF�(NYSEARCA: PEJ).
- [By Leo Sun]
With the crowdfunded Veronica Mars, which hit theaters in March, Warner convinced AMC to agree to the same-day release�by renting out its theaters. Warner retained the box office sales, in hopes that it could produce a profit after AMC's rental fees ($5,000 to $20,000 per week) were deducted. Regal and Cinemark (NYSE: CNK ) , however, do not rent out their theaters for same-day releases.
- [By Teresa Rivas]
Cinemark Holdings�(CNK) is climbing Tuesday, shaking off earlier weakness as the market digests its better-than-expected second quarter.
The company said it earned 62 cents a share on revenue of $717.9 million. Analysts were looking for earnings of 48 cents a share on revenue of $707.7 million.
Average ticket price increased 2.1% in the quarter, and concession revenues per patron grew 2.9%. Admissions overall were $455.7 million while concession sales were $226.5 million.
FBR�� Barton Crockett reiterated an Outperform rating and $39 price target: ��inemark’s 2Q14 earnings report was encouraging in a difficult period. Revenues beat our expectations on upside in box office per screen growth in Latin America and U.S. concession pricing. Adj. EBITDA beat because of U.S. expenses. Domestically, while Cinemark’s box office trend was in-line with our estimate, it did not feature the Imax/faith-based movie mix headwinds that resulted in underperformance at Regal Entertainment (RGC) and AMC Entertainment (AMC).��/p>
MKM Partners��� Eric Handler reiterated a Buy rating and $40 price target: ��e look for Cinemark’s shares to outperform the market following better than expected 2Q14 results.�Cinemark beat our/consensus estimates with upside to both domestic and Latin American results. Our positive view towards Cinemark reflects: (1) continued expansion potential of 100-125 screens annually in Latin America; and (2) projected increases in FCF over the next several years, which could lead to more regular dividend increases. The box office will likely remain choppy for the remainder of 2014, but we believe a strong two-year, global content cycle will begin in 2015.��/p>
Best Prefered Stocks To Buy Right Now: NN Inc.(NNBR)
NN, Inc. engages in the manufacture and sale of metal bearing, plastic and rubber, and precision metal components for bearing manufacturers worldwide. It operates in three segments: Metal Bearing Components, Plastic and Rubber Components, and Precision Metal Components. The Metal Bearing Components segment manufactures precision steel balls that are used primarily by manufacturers of anti-friction bearings; steel rollers comprising tapered rollers used in automotive gearbox applications, automotive wheel bearings, and various industrial applications; cylindrical rollers; and precision metal retainers for roller bearings. The Plastic and Rubber Components segment offers precision bearing seals for use in the automotive, industrial, agricultural, and mining markets; precision plastic retainers for ball and roller bearings used in various industrial applications; and precision plastic components, including automotive under-the-hood components, electronic instrument cases, pre cision electronic connectors and lenses, and various specialized industrial and consumer parts. The Precision Metal Components segment provides engineered shafts, fluid power assemblies, and complex precision assembled and tested parts used in the automotive, HVAC, fluid power, and diesel engine markets. The company was founded in 1980 and is based in Johnson City, Tennessee.
Advisors' Opinion:- [By Marc Bastow]
Precision ball-bearings and tapered rollings manufacturer NN, Inc. (NNBR) raised its quarterly dividend 16.6% to 7 cents per share, payable March 14 to shareholders of record as of Feb. 28.
NNBR Dividend Yield: 1.47% - [By Eric Volkman]
NN (NASDAQ: NNBR ) has a new man in the CEO chair. Richard Holder has been tapped to be the firm's CEO, effective June 3. He replaces the retiring Roderick Baty. Holder will also assume Baty's board seat, the term for which runs through NN's annual meeting in 2015.
Best Prefered Stocks To Buy Right Now: Sasol Ltd.(SSL)
Sasol Limited operates as an integrated energy and chemicals company worldwide. It mines saleable coal; distributes and markets natural gas and methane-rich gas; owns, operates, and maintains cross-border natural gas pipeline; produces coal-based synfuels; and markets oil products, such as petrol, diesel, jet fuel, illuminating paraffin, naphtha, liquid petroleum gas (LPG), fuel oils, bitumen, motor and industrial lubricants, and sulphur to the industrial and licensed wholesalers customers in South Africa. The company also supplies ethylene, propylene, polyethylene, polypropylene, polyvinyl chloride, chlor-alkali chemicals, and mining reagents; solvents, co-monomers, acrylates, and associated products; surfactants, linear alkylbenzene, surfactant intermediates, n-paraffins, n-olefins, C6-C22 alcohols, ethylene, oleochemicals, and other organic intermediates, as well as provides specialty aluminas, silica aluminas, and hydrotalcites. In addition, it produces and markets var ious chemical products comprising waxes, fertilizers, and mining explosive products; converts natural gas into synthesis gas for use as petrochemical feedstock; and involves in the research and development, alternative energy, and financial activities. Further, the company produces natural gas and condensate from the onshore Pande and Temane fields in Mozambique; oil in Gabon from the offshore Etame, Avouma, and Ebouri oilfield cluster; and shale gas from the Farrell Creek and Cypress A assets in Canada. It operates in South Africa, the other parts of Africa, Europe, North America, South America, Southeast Asia, Australasia, the Middle East, India, and the Far East. Sasol Limited was founded in 1950 and is headquartered in Johannesburg, South Africa.
Advisors' Opinion:- [By Dan Newman]
Profitable opportunity
Some may guess that doing business with developing countries wouldn't allow for a very profitable business. However, when South African companies like�Sasol� (NYSE: SSL ) �-- which estimated 18% of its workforce carried HIV in 2007�-- must dedicate departmental budgets to HIV/AIDS, there are plenty of opportunities for Female Health to cover costs and earn a return. A healthier workforce for Sasol would simply cost less for the company, and Female Health can help companies like Sasol achieve a healthier workforce. - [By Jeff Reeves]
If you want to play stocks directly, one great options is telecom play MTN Group�(MTNOY). Smartphones can provide even remote villages tremendous communications and commerce power to unlock growth, and MTN is a key part of that narrative across Africa. Chemicals and energy company Sasol (SSL) is more of a cyclical play but also headquartered in South Africa.
Best Prefered Stocks To Buy Right Now: Och-Ziff Capital Management Group LLC(OZM)
Och-Ziff Capital Management Group LLC is a publicly owned investment manager. The firm provides investment advisory services for its clients. It invests in equity markets across the world. The firm makes its investments in alternative markets across the world. It employs quantitative and qualitative analysis to make its investments. The firm also manages a buyout fund, Och-Ziff Energy Fund. Och-Ziff Capital Management Group LLC was founded in 1994 and is based New York, New York with additional offices in London, United Kingdom; Hong Kong; Tokyo, Japan; Bangalore, India; and Beijing, China.
Advisors' Opinion:- [By James Brumley]
In the meantime, the 9%-plus dividend yield — at 40 cents per share, which is a dime better than SFL stock paid out in 2009 — is nothing to sneeze at.
Och-Ziff Capital Management Group LLC (OZM)OZM Dividend Yield: 13.6%
- [By MONEYMORNING]
Although there are many great companies to choose from in the alternative investment management space, there are two that I really like, and that investors should consider owning. The first is hedge fund titan Och-Ziff Capital Management Group LLC (NYSE: OZM).
Best Prefered Stocks To Buy Right Now: Haemonetics Corp (HAE)
Haemonetics Corporation, incorporated on August 29, 1985, is a healthcare company engaged in providing blood management solutions to its customers. The Company�� portfolio of integrated devices, information management and consulting services offers blood management solutions for each facet of the blood supply chain, helping improve clinical outcomes and reduce costs for blood and plasma collectors, hospitals, and patients around the world.The Company serves three markets: manufacturers of plasma derived pharmaceuticals, blood collectors and hospitals. Plasma includes plasma collection devices and consumables. Blood Center includes blood collection and processing devices and consumables. Hospital includes surgical blood salvage and blood demand diagnostic devices and consumables. Software Solutions includes information technology platforms and consulting services provided to all three markets. On April 30, 2013, the Company acquired of certain assets of Hemerus LLC.
The Company helps its customers create and maintain a safe and efficient blood supply chain. Specifically, it develops and markets a wide range of systems used with plasma and blood donors that collect and process blood into its components using both manual and automated methods. It also develops and markets a variety of systems to hospitals that automate the cleaning and reinfusion of a surgical patient's blood during surgery, automate the tracking and distribution of blood in the hospital, and enhance blood diagnostics. The Company sells information technology platforms to promote efficient and compliant operations for all of its customer groups. The Company provides consulting services to reduce costs and improve operating efficiencies in blood management. . Its products and services help prevent a transfusion to a patient who does not need one and provide the right blood product, at the right time, in the right dose to the patient who does.
Plasma
Human plasma is collected and processed by bio-ph! armaceutical companies into therapeutic and diagnostic products that aid in the treatment of immune diseases and coagulation disorders. While plasma is also used to aid patients with extreme blood loss, such as trauma victims, this portion of its business solely focuses on plasma's pharmaceutical uses. Automated plasma collection technology allows for the safe and efficient collection of plasma. The Company manufactures and market plasma collection devices and respective disposables, but do not make plasma-derived pharmaceuticals.
The Company�� portfolio of products and services is designed to support multiple facets of plasma collector operations. The Company with its PCS brand automated plasma collection technology, more plasma can be collected during any one donation event because the other blood components are returned to the donor through the sterile disposable sets used for the plasma donation procedure. The Company offers one stop shopping to its plasma collection customers, enabling them to source from them the full range of products necessary for plasma collection and storage, including PCS brand plasma collection equipment and consumables, plasma collection containers, and intravenous solutions. It also offers a robust portfolio of integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain. Its products automate the donor interview and qualification process; streamline the workflow process in the plasma center; provide the controls necessary to evaluate donor suitability; determine the ability to release units collected; and manage unit distribution.
Blood Center
The Company offers automated blood component and manual whole blood collection systems to blood collection centers to collect blood products.The Company markets the MCS (Multicomponent Collection System) brand apheresis equipment which is designed to collect specific blood components integrated from the donor. Utilizing t! he MCS au! tomated platelet collection protocols, blood centers collect one or more therapeutic doses of platelets during a single donation by a volunteer blood donor. The MCS two-unit protocol or double red cell collection device helps blood collectors optimize the collection of red cells by automating the blood separation function, eliminating the need for laboratory processing, and enabling the collection of two units of red cells from a single donor thus maximizing the amount of red cells collected per eligible donor and helping to mitigate red cell shortages in countries where this problem exists. Blood collectors can also use the MCS system to collect one unit of red cells and a jumbo (double) unit of plasma, or one unit of red cells and one unit of platelets from a single donor. The MCS plasma protocol providing the possibility to collect 600-800ml of plasma for transfusion to patients or for pharmaceutical industry use completes the comprehensive portfolio of different blood component collection options on this device.
The Company offers a portfolio of products for manual whole blood collection and processing. Haemonetics' portfolio of disposable whole blood collection and component storage sets offer flexibility in collecting a unit of whole blood and the subsequent production and storage of the red blood cell, platelet, and/or plasma products, including options for in-line or dockable filters for leukoreduction of any blood component. In addition Acrodose product line provides a closed system for the pooling, storage, and bacteria testing of leukoreduced whole blood derived platelet concentrates, an Acrodose Platelet, that is transfusion ready for the hospital. Use of Acrodose platelets lowers hospital handling costs by eliminating the need for pooling and bacteria testing at the hospital.
The Company with ACP(Automated Cell Processor) brand offers a small bench-top solution to automate the washing and freezing of red cell components in the lab. The automated red cell was! hing proc! edure removes plasma proteins within the red cell units to provide a safer product for transfusion to frequently transfused patients, neonates, or patients with a history of transfusion reactions. The automated glycerolization and deglycerolization steps are required to prepare red cells for frozen storage. Freezing the red cell units can expand the shelf life of these products up to 10 years. Customers utilize this technology to implement strategic red cell inventories for catastrophe cases, storage of rare blood types, or enhanced inventory management.
Hospital
The Company offers a range of blood management solutions that significantly improve a hospital's systems for acquiring blood, storing it in the hospital, and dispensing it efficiently and correctly. Its products and integrated solution platforms help hospitals optimize performance of blood acquisition, storage, and distribution.The Company�� TEG Thrombelastograph Hemostasis Analyzer system is a blood diagnostic instrument that measures a patient's hemostasis or the ability to form and maintain blood clots.
The Cell Saver system is a surgical blood salvage system targeted to procedures that involve rapid, high-volume blood loss, such as cardiovascular surgeries. It has become the standard of care for high blood-loss surgeries. During the year ended December 31,2012, the Company launched the Cell Saver Elite system, which is autotransfusion option to minimize allogeneic blood use for surgeries with medium to high blood loss. The OrthoPAT surgical blood salvage system is targeted to procedures, such as orthopedic, that involve slower, lower volume blood loss that often occurs well after surgery. The cardioPAT system is a surgical blood salvage system targeted to open heart surgeries when there is less blood loss during surgery, but where the blood loss continues post-surgery. These systems are designed to remain with the patient following surgery, to recover blood and produce a washed red cell produ! ct for au! totransfusion. Their Quick-Connect feature permits customers to utilize the blood processing set selectively, depending on the patient's need.
The Company�� IMPACT Online Web-based software platform, which monitors and measures improvements in a hospital�� blood management practices, provides hospitals with a baseline view of their blood management metrics and helps monitor transfusion rates. Business consulting solutions are offered to support process and blood management efforts. It also provides blood management assessment tools to hospitals that enables its customers to monitor their progress in order to continually improve their blood management performance.
Software Solutions
The Companby has a suite of integrated software solutions for improving efficiencies and helping ensure donor and patient safety. This includes solutions for blood drive planning, donor recruitment and retention, blood collection, component manufacturing and distribution, transfusion management, and remote blood allocation. For its plasma customers, it also provides information technology platforms for managing donors and information associated with the collection of plasma products within fractionation facilities.
The Company�� software solutions , including information technology platforms and consulting services can be combined with its devices and sold through its plasma, blood center, and hospital sales forces. The Company�� software products help hospitals track and safely deliver stored blood products. SafeTrace Tx is its software solution that helps manage blood product inventory, perform patient cross-matching, and manage transfusions. In addition, its BloodTrack suite of solutions manages tracking and control of blood products from the hospital blood center through to transfusion to the patient. Smart refrigerators located in or near operating suites, emergency rooms, and other parts of the hospital dispense blood units with secure control and autom! ated trac! eability for efficient documentation. With its offerings, hospitals are better able to manage processes across the blood supply chain and identify increased opportunities to reduce costs and enhance processes. Its software solutions, such as its SafeTrace and El Dorado Donor donation and blood unit management systems, span blood center operations and automate and track operations from the recruitment of the blood donor to the disposition of the blood product. Its Hemasphere software solution provides support for more efficient blood drive planning, and Donor Doc and e-Donor software help to improve recruitment and retention.
The Company competes with Fenwal, Inc., Terumo BCT ,Caridian BCT, Rotem, MAK Systems, Mediware, MacoPharma , Medtronic, Fresenius, Sunquest Information Systems and Sorin Biomedica.
Advisors' Opinion:- [By Lisa Levin]
Haemonetics (NYSE: HAE) shares fell 8.57% to reach a new 52-week low of $30.40 after the company Q4 adjusted earnings of $0.46 per share on revenue of $241.10 million. The company's board also announced a $100 million share buyback program.
- [By Monica Gerson]
Analysts at Benchmark downgraded Haemonetics (NYSE: HAE) from ��uy��to ��old.��The target price for Haemonetics has been lowered from $49 to $46.
No comments:
Post a Comment